Therapeutic Asset Ratings

8,400 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Eflornithine Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype	Mayo Clinic	P1/2	CCC (52)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) Renal Pelvis Urothelial Carcinoma	Fred Hutchinson Cancer Center	P1/2	CCC (52)
Entacapone Multiple System Atrophy	Daniel Claassen	P1/2	CCC (52)
Epirubicin Adenoid Cystic Carcinoma	Seagen, a wholly owned subsidiary of Pfizer	P1/2	CCC (52)
Epirubicin Microsatellite Instability High	NextCure, Inc.	P1/2	CCC (52)
Epirubicin Uterine Cancer	Genmab	P1/2	CCC (52)
esg401 Gastric Neoplasm	Shanghai Escugen Biotechnology Co., Ltd	P1/2	CCC (52)
esg401 Colorectal Neoplasm	Shanghai Escugen Biotechnology Co., Ltd	P1/2	CCC (52)
esg401 Lung Neoplasm	Shanghai Escugen Biotechnology Co., Ltd	P1/2	CCC (52)
esg401 Ovarian Cancer	Shanghai Escugen Biotechnology Co., Ltd	P1/2	CCC (52)
ETOPOSIDE B-Cell Neoplasm	National Cancer Institute (NCI)	P1/2	CCC (52)
ETOPOSIDE Prostate Neuroendocrine Neoplasm	Phanes Therapeutics	P1/2	CCC (52)
FALLYPRIDE Lymphoid Malignancies	National Cancer Institute (NCI)	P1/2	CCC (52)
Favezelimab Esophageal Squamous Cell Carcinoma	Merck Sharp & Dohme LLC	P1/2	CCC (52)
FLAVONE, 3,3',4',5,7-PENTAHYDROXY- Metabolic Dysfunction-Associated Steatohepatitis	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	P1/2	CCC (52)
Fludarabine Anal Squamous Cell Carcinoma	SCG Cell Therapy Pte. Ltd.	P1/2	CCC (52)
Fludarabine B-Cell Neoplasm	Han weidong	P1/2	CCC (52)
Fludarabine Colon Carcinoma	Essen Biotech	P1/2	CCC (52)
Fludarabine Peritoneum Cancer	Peking University	P1/2	CCC (52)
Fludarabine Relapsed Adult AML	Masonic Cancer Center, University of Minnesota	P1/2	CCC (52)
Fludarabine Synovial Sarcoma	Zelluna Immunotherapy AS	P1/2	CCC (52)
FLUOROURACILUM Prostate Cancer	Parabilis Medicines, Inc.	P1/2	CCC (52)
Forimtamig Plasma Cell Myeloma	Hoffmann-La Roche	P1/2	CCC (52)
FULVESTRANT HR+ HER2- Breast Cancer	Faeth Therapeutics	P1/2	CCC (52)
FULVESTRANT MEK1 Gene Mutation	Memorial Sloan Kettering Cancer Center	P1/2	CCC (52)

Showing 551 to 575 of 8,400 assets

PreviousPage 23 of 336Next